和黃醫藥(00013.HK)宣佈沃瑞沙® (ORPATHYS®)和泰瑞沙® (TAGRISSO®)的聯合療法的SANOVO研究在中國伴有MET過表達的EGFR突變肺癌初治患者中顯示出顯著的無進展生存期獲益

智通財經

08/31

【和黃醫藥(00013.HK)宣佈沃瑞沙® (ORPATHYS®)和泰瑞沙® (TAGRISSO®)的聯合療法的SANOVO研究在中國伴有MET過表達的EGFR突變肺癌初治患者中顯示出顯著的無進展生存期獲益】智通財經APP訊，和黃醫藥(00013.HK)發布公告，在初治的伴有表皮生長因子受體(「EGFR」)突變和MET過表達的局部晚期或轉移性非小細胞肺癌患者中開展的SANOVO中國III期研究取得積極的頂線結果。沃瑞沙®(ORPATHYS®，賽沃替尼/ savolitinib)和泰瑞沙®(TAGRISSO®，奧希替尼/ osimertinib)的聯合療法對比泰瑞沙®單藥在高水平MET以及意向治療 (intent-to-treat)患者人群中均顯示出統計學顯著且具有高度臨床意義的無進展生存期(「PFS」)改善。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2663282840"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2663282840\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2663282840?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-31 08:11","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2663282840","market":"hk","top_or_hot":-1,"title":"和黃醫藥(00013.HK)宣佈沃瑞沙® (ORPATHYS®)和泰瑞沙® (TAGRISSO®)的聯合療法的SANOVO研究在中國伴有MET過表達的EGFR突變肺癌初治患者中顯示出顯著的無進展生存期獲益","media":"智通財經","content":"<html><body><div>\n<div>\n<b>【和黃醫藥(00013.HK)宣佈沃瑞沙® (ORPATHYS®)和泰瑞沙® (TAGRISSO®)的聯合療法的SANOVO研究在中國伴有MET過表達的EGFR突變肺癌初治患者中顯示出顯著的無進展生存期獲益】</b>智通財經APP訊，和黃醫藥(00013.HK)發布公告，在初治的伴有表皮生長因子受體(「EGFR」)突變和MET過表達的局部晚期或轉移性非小細胞肺癌患者中開展的SANOVO中國III期研究取得積極的頂線結果。沃瑞沙®(ORPATHYS®，賽沃替尼/ \n\nsavolitinib)和泰瑞沙®(TAGRISSO®，奧希替尼/ osimertinib)的聯合療法對比泰瑞沙®單藥在高水平MET以及意向治療 \n\n(intent-to-treat)患者人群中均顯示出統計學顯著且具有高度臨床意義的無進展生存期(「PFS」)改善。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和黃醫藥(00013.HK)宣佈沃瑞沙® (ORPATHYS®)和泰瑞沙® (TAGRISSO®)的聯合療法的SANOVO研究在中國伴有MET過表達的EGFR突變肺癌初治患者中顯示出顯著的無進展生存期獲益</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和黃醫藥(00013.HK)宣佈沃瑞沙® (ORPATHYS®)和泰瑞沙® (TAGRISSO®)的聯合療法的SANOVO研究在中國伴有MET過表達的EGFR突變肺癌初治患者中顯示出顯著的無進展生存期獲益\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2026-08-31 08:11</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【和黃醫藥(00013.HK)宣佈沃瑞沙® (ORPATHYS®)和泰瑞沙® (TAGRISSO®)的聯合療法的SANOVO研究在中國伴有MET過表達的EGFR突變肺癌初治患者中顯示出顯著的無進展生存期獲益】</b>智通財經APP訊，和黃醫藥(00013.HK)發布公告，在初治的伴有表皮生長因子受體(「EGFR」)突變和MET過表達的局部晚期或轉移性非小細胞肺癌患者中開展的SANOVO中國III期研究取得積極的頂線結果。沃瑞沙®(ORPATHYS®，賽沃替尼/ \n\nsavolitinib)和泰瑞沙®(TAGRISSO®，奧希替尼/ osimertinib)的聯合療法對比泰瑞沙®單藥在高水平MET以及意向治療 \n\n(intent-to-treat)患者人群中均顯示出統計學顯著且具有高度臨床意義的無進展生存期(「PFS」)改善。                </div>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"半新股","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2663282840","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2663282840","pubTimestamp":1788135109,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【和黃醫藥(00013.HK)宣佈沃瑞沙® (ORPATHYS®)和泰瑞沙® (TAGRISSO®)的聯合療法的SANOVO研究在中國伴有MET過表達的EGFR突變肺癌初治患者中顯示出顯著的無進展生存","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1587":"次新股","BK1191":"制药","00013":"和黄医药","BK1588":"回港中概股"},"translate_title":"Hutchison MediPharma (00013.HK) announced Warissa ® (ORPATHYS ® ) and Teresa ® (TAGRISSO ® The SANOVO study of combination therapy showed significant progression-free survival benefits in Chinese patients with newly treated EGFR-mutant lung cancer with MET overexpression.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1.5},"content_text":"【和黃醫藥(00013.HK)宣佈沃瑞沙® (ORPATHYS®)和泰瑞沙® (TAGRISSO®)的聯合療法的SANOVO研究在中國伴有MET過表達的EGFR突變肺癌初治患者中顯示出顯著的無進展生存期獲益】智通財經APP訊，和黃醫藥(00013.HK)發布公告，在初治的伴有表皮生長因子受體(「EGFR」)突變和MET過表達的局部晚期或轉移性非小細胞肺癌患者中開展的SANOVO中國III期研究取得積極的頂線結果。沃瑞沙®(ORPATHYS®，賽沃替尼/ \n\nsavolitinib)和泰瑞沙®(TAGRISSO®，奧希替尼/ osimertinib)的聯合療法對比泰瑞沙®單藥在高水平MET以及意向治療 \n\n(intent-to-treat)患者人群中均顯示出統計學顯著且具有高度臨床意義的無進展生存期(「PFS」)改善。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}